Lisa Baumann Kreuziger
YOU?
Author Swipe
View article: Cytoreductive therapy reduces recurrent thrombosis in patients with myeloproliferative neoplasm-associated splanchnic vein thrombosis: A global abdominal/splanchnic thrombosis retrospective observational study (GASTRO-MPN) study of 757 patients
Cytoreductive therapy reduces recurrent thrombosis in patients with myeloproliferative neoplasm-associated splanchnic vein thrombosis: A global abdominal/splanchnic thrombosis retrospective observational study (GASTRO-MPN) study of 757 patients Open
Background Patients with myeloproliferative neoplasms (MPNs) are at risk of splanchnic vein thrombosis (SVT). Prior studies failed to demonstrate a benefit of hydroxyurea in preventing SVT extension/recurrence, but these were limited by sm…
View article: Impact of thrombocytopenia on hemorrhage and recurrent thrombosis in patients with cancer associated thrombosis, a time varying analysis
Impact of thrombocytopenia on hemorrhage and recurrent thrombosis in patients with cancer associated thrombosis, a time varying analysis Open
IntroductionBoth venous thromboembolism (VTE) and thrombocytopenia are frequent complications in patients with cancer. Managing cancer associated thrombosis (CAT) in the setting of thrombocytopenia presents a significant clinical challenge…
View article: The Red Blood Cell-Improving Transfusions for Chronically Transfused Recipients (RBC-IMPACT) study: protocol description of an international multi-site observational clinical study.
The Red Blood Cell-Improving Transfusions for Chronically Transfused Recipients (RBC-IMPACT) study: protocol description of an international multi-site observational clinical study. Open
This study will be the most detailed and granular evaluation of the predictive variables that may optimize RBC effectiveness and safety in these chronically transfused patient populations.
View article: Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Reversal of Anticoagulation: Evaluation of Efficacy, Safety, and Cost Savings
Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Reversal of Anticoagulation: Evaluation of Efficacy, Safety, and Cost Savings Open
Fixed-dosing of 4F-PCC had significantly less cost than adjusted dose and is associated with similar rates of thrombosis and death compared to other studies.
View article: Race, rituximab, and relapse in TTP
Race, rituximab, and relapse in TTP Open
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by recurring episodes of thrombotic microangiopathy, causing ischemic organ impairment. Black patients are overrepresented in iTTP cohorts in the United States, bu…
View article: Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization
Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization Open
BACKGROUND: Patients hospitalized with COVID-19 have an increased incidence of thromboembolism. The role of extended thromboprophylaxis after hospital discharge is unclear. OBJECTIVE: To determine whether anticoagulation is superior to pla…
View article: Multinational cohort study of intracranial hemorrhage in patients with brain metastases receiving anticoagulation
Multinational cohort study of intracranial hemorrhage in patients with brain metastases receiving anticoagulation Open
Not available.
View article: 40 is the new 50: reducing the need for platelet transfusions prior to lumbar puncture in adults with hematologic malignancies
40 is the new 50: reducing the need for platelet transfusions prior to lumbar puncture in adults with hematologic malignancies Open
Not available.
View article: Relapse Free Survival Progressive Shortens in a Subset of Black patients with Immune TTP Treated in the Rituximab Era
Relapse Free Survival Progressive Shortens in a Subset of Black patients with Immune TTP Treated in the Rituximab Era Open
Immune thrombotic thrombocytopenic purpura (iTTP) is a chronically relapsing disorder caused by autoantibody mediated deficiency of ADAMTS13. Rituximab is frequently administered to prevent relapses, but whether the durability of rituximab…
View article: Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era
Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era Open
Immune thrombotic thrombocytopenic purpura (iTTP) is a chronically relapsing disorder caused by autoantibody-mediated deficiency of ADAMTS13. Rituximab is frequently administered to prevent relapses, but whether the durability of rituximab…
View article: Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation
Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation Open
Introduction Spontaneous intracerebral hemorrhage (sICH) frequently occurs in patients with primary or metastatic brain tumors treated with anticoagulation and presents primarily as intratumoral bleeding. While an association between the b…
View article: Comparative Analysis of Perioperative Anticoagulation Management Guidelines across U.S. Institutions
Comparative Analysis of Perioperative Anticoagulation Management Guidelines across U.S. Institutions Open
Introduction Guidelines for perioperative management of oral anticoagulants exist to balance the risk of bleeding against thromboembolism. We evaluated the implementation of international guidelines into US hospital guidelines. Methods The…
View article: A Subset of Antibodies to the Spike Protein's Receptor-Binding Domain in Severe COVID-19 Activate Platelets
A Subset of Antibodies to the Spike Protein's Receptor-Binding Domain in Severe COVID-19 Activate Platelets Open
Severe COVID-19 is a multisystem condition with thromboinflammation as a significant driver of morbidity and mortality. Cellular components involved in inflammatory and coagulation responses include platelets, endothelium, monocytes, and n…
View article: Prevalence of Iron Deficiency in Reproductive-Age Females on Anticoagulation for Venous Thromboembolism
Prevalence of Iron Deficiency in Reproductive-Age Females on Anticoagulation for Venous Thromboembolism Open
Introduction Heavy menstrual bleeding (HMB) occurs in up to 70% of reproductive-age females on anticoagulation. HMB can lead to iron deficiency with or without anemia, which can cause profound symptoms, affect organ function, and diminish …
View article: Anticoagulation Management of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A Global Abdominal/Splanchnic Thrombosis Retrospective Observational Study in 486 MPN Patients (GASTRO-MPN)
Anticoagulation Management of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A Global Abdominal/Splanchnic Thrombosis Retrospective Observational Study in 486 MPN Patients (GASTRO-MPN) Open
Background: Myeloproliferative neoplasms (MPNs) are chronic leukemias with increased thrombotic risk. Venous thrombosis in MPN often occurs in atypical sites, such as splanchnic vein thrombosis (SVT), defined by thrombosis in the portal, h…
View article: Variation in Anticoagulant Hemorrhage Management Guidelines for Factor-Xa Inhibitors: A Survey and Analysis of U.S. Academic Institutions
Variation in Anticoagulant Hemorrhage Management Guidelines for Factor-Xa Inhibitors: A Survey and Analysis of U.S. Academic Institutions Open
Background Andexanet alfa (AA) is a decoy protein that acts by binding and sequestering factor-Xa inhibitors. Approved by the United States (US) Food and Drug Administration in 2018, it is indicated for reversing the anticoagulation effect…
View article: Anemia From Inflammation After Intracerebral Hemorrhage and Relationships With Outcome
Anemia From Inflammation After Intracerebral Hemorrhage and Relationships With Outcome Open
Background Baseline anemia is associated with poor intracerebral hemorrhage (ICH) outcomes. However, underlying drivers for anemia and whether anemia development after ICH impacts clinical outcomes are unknown. We hypothesized that inflamm…
View article: High-risk subgroups were not identified to benefit from thromboprophylaxis after hospitalization for COVID-19
High-risk subgroups were not identified to benefit from thromboprophylaxis after hospitalization for COVID-19 Open
The combined incidence of 30-day death, ATE, and VTE was low in patients who survived COVID-19 hospitalization, except in patients over age 60 years. Due to the limited number of events, the findings remain inconclusive; nonetheless, the s…
View article: A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura
A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura Open
The USTMA Mortality Index was acceptable for predicting mortality due to acute iTTP in the USTMA registry, but not sensitive enough to rule out death. Identifying patients at high risk of iTTP-related mortality may help individualize care …
View article: Primary Care Clinicians’ Prescribing Patterns of Reduced-Dose Direct Oral Anticoagulants for Extended-Phase Venous Thromboembolism Treatment
Primary Care Clinicians’ Prescribing Patterns of Reduced-Dose Direct Oral Anticoagulants for Extended-Phase Venous Thromboembolism Treatment Open
The direct anticoagulants (DOACs), apixaban and rivaroxaban, are used for extended-phase treatment of venous thromboembolism (VTE) and have labeling for dose reduction for this indication. The objective of this study was to better understa…
View article: A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry
A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry Open
[Figure: see text]